1
|
Bursi S, Anzolin F, Natale S, Onfiani G, Morisi L, Tommesani G, Corradini B, Valeriani L. EARLY NUTRITION PROTOCOL FOR IN- AND OUT-PATIENTS DURING COVID-19 PANDEMIC. Nutrition 2021. [PMCID: PMC8238424 DOI: 10.1016/j.nut.2021.111333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
Objective Recent SARS-COV2 pandemic put Healthcare System in severe overload. It is well demonstrated that malnutrition is related to worse outcomes in acute and chronic diseases. During this sanitary emergency the Clinical Nutrition Unit in Bologna developed an early nutrition protocol for hospital ad home COVID-19 patients. Methods and procedures Recently published recommendations regarding nutritional needs in COVID-19 patients and general Clinical Nutrition Guidelines were searched on PubMed. Results The hospital algorithm considered three different steps: oral feeding, enteral feeding and parenteral nutrition, recommending early nutrition therapy (within 24-48 hours of hospitalization). We arranged a modified oral "COVID diet" consisting in soft or creamy hypercaloric-hyperproteic meals in disposable packages . As far as artificial nutrition is concerned we chose hypercaloric, high-protein Oral Nutrition Supplements (ONS), enteral formulas and parenteral formulas, all enriched with EPA and DHA. Due to high micronutrients requirements each patient was recommended high-dose uniparenteral vitamin D and thiamine. For home COVID-19 patients screening using NRS-2003 was recommended: for those at low nutritional risk we provided general nutritional advice; for those at intermediate risk we suggested a dietitian consultation for personalized nutritional plan or ONS prescription. For those at high nutritional risk the nutritionist physician evaluation was suggested for disease-specific ONS or artificial nutrition prescription. All patients were suggested vitamin D 2000 IU / day and a multivitamin supplement. Conclusion During COVID-19 pandemic continuous clinical updating and adaptation to new clinical settings helped to develop an Early Nutrition Protocol for fast nutritional assessment and treatment in a large number of patients and emergency conditions.
Collapse
|
2
|
Nascimbeni F, Lugari S, Cassinerio E, Motta I, Cavicchioli A, Dalla Salda A, Bursi S, Donatiello S, Spina V, Cappellini MD, Andreone P, Carubbi F. Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease. Liver Int 2020; 40:3061-3070. [PMID: 32810900 DOI: 10.1111/liv.14640] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2020] [Revised: 07/24/2020] [Accepted: 08/08/2020] [Indexed: 12/14/2022]
Abstract
BACKGROUND AND AIMS Gaucher disease (GD) is associated with peculiar metabolic abnormalities (ie hypermetabolic state, peripheral insulin resistance, dyslipidaemia), partially reverted by enzyme replacement therapy (ERT) at the expense of weight gain. Such metabolic alterations together with an unhealthy lifestyle acquired by an ageing GD population may favour the development of liver steatosis. We aimed at evaluating the prevalence of significant liver steatosis and at identifying the factors associated with liver steatosis in a cohort of patients with type 1 GD. METHODS Twenty adult type 1 GD patients from an Italian academic referral centre were prospectively submitted to vibration-controlled transient elastography (Fibroscan®) with controlled attenuation parameter (CAP); significant steatosis was defined as CAP values ≥250 dB/min. RESULTS Median CAP values were 234 [165-358] dB/min and 8 patients (40%) had significant steatosis. Significant steatosis was associated with indices of adiposity (weight, BMI and waist circumference), high blood pressure, insulin resistance and metabolic syndrome. GD-related variables and dose and duration of ERT were not associated with significant steatosis. In the subgroup of 16 patients on stable ERT for at least 24 months, CAP resulted significantly and positively associated with liver stiffness (rho 0.559, P = .024). CONCLUSIONS Significant steatosis is highly prevalent in adult type 1 GD patients and is strongly associated with a worse metabolic profile, featuring metabolic dysfunction-associated fatty liver disease (MAFLD). MAFLD may determine liver fibrosis progression in GD patients on stable ERT and may be a risk factor for long-term liver-related complications.
Collapse
Affiliation(s)
- Fabio Nascimbeni
- Regional Referral Centre for Lysosomal Storage Diseases, Division of Internal Medicine and Metabolism, Civil Hospital, AOU of Modena, University of Modena and Reggio Emilia, Modena, Italy
| | - Simonetta Lugari
- Regional Referral Centre for Lysosomal Storage Diseases, Division of Internal Medicine and Metabolism, Civil Hospital, AOU of Modena, University of Modena and Reggio Emilia, Modena, Italy
| | - Elena Cassinerio
- Rare Diseases Centre, Department of Medicine and Medical Specialities, "Ca' Granda" Foundation IRCCS, Milan, Italy
| | - Irene Motta
- Rare Diseases Centre, Department of Medicine and Medical Specialities, "Ca' Granda" Foundation IRCCS, Milan, Italy
| | - Alessia Cavicchioli
- Regional Referral Centre for Lysosomal Storage Diseases, Division of Internal Medicine and Metabolism, Civil Hospital, AOU of Modena, University of Modena and Reggio Emilia, Modena, Italy
| | - Annalisa Dalla Salda
- Regional Referral Centre for Lysosomal Storage Diseases, Division of Internal Medicine and Metabolism, Civil Hospital, AOU of Modena, University of Modena and Reggio Emilia, Modena, Italy
| | - Serena Bursi
- Regional Referral Centre for Lysosomal Storage Diseases, Division of Internal Medicine and Metabolism, Civil Hospital, AOU of Modena, University of Modena and Reggio Emilia, Modena, Italy
| | | | - Vincenzo Spina
- Radiology Division, Civil Hospital, AOU of Modena, Modena, Italy
| | - Maria Domenica Cappellini
- Rare Diseases Centre, Department of Medicine and Medical Specialities, "Ca' Granda" Foundation IRCCS, Milan, Italy
| | - Pietro Andreone
- Regional Referral Centre for Lysosomal Storage Diseases, Division of Internal Medicine and Metabolism, Civil Hospital, AOU of Modena, University of Modena and Reggio Emilia, Modena, Italy
| | - Francesca Carubbi
- Regional Referral Centre for Lysosomal Storage Diseases, Division of Internal Medicine and Metabolism, Civil Hospital, AOU of Modena, University of Modena and Reggio Emilia, Modena, Italy
| |
Collapse
|
3
|
Lugari S, Nascimbeni F, Mondelli A, Bursi S, Onfiani G, Milazzo M, Pellegrini E, Carubbi F. Efficacy And Safety Of Pcsk9 Inhibitors: The Real-Life Experience Of The Lipid Clinic In Modena, Italy. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
4
|
Nascimbeni F, Cassinerio E, Dalla Salda A, Motta I, Bursi S, Donatiello S, Spina V, Cappellini MD, Carubbi F. Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease. Mol Genet Metab 2018; 125:64-72. [PMID: 30115580 DOI: 10.1016/j.ymgme.2018.08.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2018] [Revised: 08/09/2018] [Accepted: 08/10/2018] [Indexed: 02/06/2023]
Abstract
BACKGROUND & AIMS Long-term liver-related complications of Gaucher disease (GD) include cirrhosis, portal hypertension and hepatocellular carcinoma. Although liver fibrosis is the main determinant of adverse liver-related clinical outcomes, it has rarely been evaluated in previously published cohorts of GD patients. We aimed at: assessing the prevalence of significant liver fibrosis in a cohort of patients with type 1 GD; identifying its predictors among GD-related variables, enzyme replacement therapy (ERT) and metabolic features. METHODS 37 adult type 1 GD patients from two Italian academic referral centers were prospectively submitted to vibration controlled transient elastography (Fibroscan®); significant fibrosis was defined as liver stiffness ≥7 kPa. RESULTS Median liver stiffness was 4.6 [3-15.1] kPa and 7 patients (19%) had significant fibrosis. Significant fibrosis was associated with splenectomy (p = .046) and with scores (DS3: p = .002; SSI: p = .026) and biomarkers (ACE: p = .016; HDL cholesterol: p = .004) of GD severity. Length of ERT was significantly lower in GD patients with significant fibrosis. In the subgroup of 29 patients who were on stable ERT for at least 24 months, further to splenectomy, GD severity and non-N370S GBA1 genotypes, also diastolic blood pressure, BMI and the number of metabolic syndrome (MetS) components emerged as factors significantly associated with significant fibrosis. CONCLUSIONS Significant fibrosis is present in a remarkable proportion of adult type 1 GD patients. Splenectomy, GD severity and GBA1 genotypes are major GD-related predictors of liver fibrosis. Length of ERT is inversely correlated with liver disease in GD patients, suggesting a beneficial effect of ERT on liver fibrosis. However, GD patients on stable ERT should be monitored for metabolic complications, since MetS features may enhance liver disease progression despite optimal GD control.
Collapse
Affiliation(s)
- Fabio Nascimbeni
- Regional Referral Centre for Lysosomal Storage Diseases, Division of Internal Medicine and Metabolism, Civil Hospital, AOU Modena, University of Modena and Reggio Emilia, Modena, Italy
| | - Elena Cassinerio
- Rare Diseases Center, Department of Medicine, "Ca' Granda" Foundation IRCCS, Milan, Italy
| | - Annalisa Dalla Salda
- Regional Referral Centre for Lysosomal Storage Diseases, Division of Internal Medicine and Metabolism, Civil Hospital, AOU Modena, University of Modena and Reggio Emilia, Modena, Italy
| | - Irene Motta
- Rare Diseases Center, Department of Medicine, "Ca' Granda" Foundation IRCCS, Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Italy
| | - Serena Bursi
- Regional Referral Centre for Lysosomal Storage Diseases, Division of Internal Medicine and Metabolism, Civil Hospital, AOU Modena, University of Modena and Reggio Emilia, Modena, Italy
| | | | - Vincenzo Spina
- Radiology Division, Civil Hospital, AOU, Modena, Modena, Italy
| | - Maria Domenica Cappellini
- Rare Diseases Center, Department of Medicine, "Ca' Granda" Foundation IRCCS, Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Italy
| | - Francesca Carubbi
- Regional Referral Centre for Lysosomal Storage Diseases, Division of Internal Medicine and Metabolism, Civil Hospital, AOU Modena, University of Modena and Reggio Emilia, Modena, Italy.
| |
Collapse
|
5
|
Sacchetti A, Mattei G, Bursi S, Padula M, Rioli G, Ferrari S. Association of blood pressure with anxiety and depression in a sample of primary care patients. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.614] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
IntroductionAccording to international scientific literature, and as summarized in the guidelines of the International Society of Hypertension, lowering of blood pressure can prevent cardiovascular accidents. Some studies suggest that hypertension, anxiety, and depression might be inversely correlated.ObjectiveTo investigate whether blood pressure is associated with anxiety and depression.MethodsCross-sectional design. Male and female primary care patients were enrolled, aged 40–80. Criteria of exclusion adopted: use of antidepressants or antipsychotics; previous major cardiovascular event; psychosis or major depression; Type 1-DM; pregnancy and hereditary disease associated to obesity. Anxiety and depression symptoms were assessed using HADS. Waist circumference, hip circumference, blood pressure, HDL, triglycerides, blood sugar, hypertension, albumin concentrations and serum iron were also assessed.ResultsOf the 210 subjects, 84 were men (40%), mean age was 60.88 (SD ± 10.88). Hypertension was found to correlate significantly to anxiety (OR = 0.38; 95% CI = 0.17–0.84), older age (OR = 3.96; 95% CI = 1.88–8.32), cigarette smoking (OR = 0.35; 95%CI = 0.13–0.94), high Body Mass Index (OR = 2.50; 95% CI = 1.24–5.01), Waist-hip ratio (OR = 0.09; 95% CI = 0.02–0.46) and the Index of comorbidity (OR = 16.93; 95% CI = 3.71–77.29).ConclusionsAn inverse association was found between anxiety and hypertension, suggesting the need to clinically manage these two dimensions in a coordinated way. Other findings are well known and already included in prevention campaigns. Further research is needed, also to better understand and explain the causative pathways of this correlation.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
6
|
Mattei G, Bursi S, Bursi R, Colantoni A. Bridging the gap between clinical practice and research: The association for research in psychiatry. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.1356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
Clinical practice and research are frequently seen as two worlds apart, in psychiatry as in the vast majority of medical specialties. In order to bridge the gap between them, economic founds and grants are required, not always easy to obtain. In this contribution we report the birth of the Association for Research in Psychiatry (ARPSY) and its main activities. ARPSY was born in May 2016 thanks to a research prize assigned to dr. Giorgio Mattei by the eight Rotary Clubs of the Province of Modena, Italy (Rotary Club Modena, Mirandola, Carpi, Sassuolo, Vignola Castelfranco Bazzano, Frignano, Modena L.A. Muratori, Castelvetro di Modena Terra dei Rangoni, that altogether make up the so-called “Ghirlandina Group”). Aim of the association is to promote mental health among students and trainees, mental health professionals, patients and their families, and among the general population by means of fund raising, in order to finance research projects, clinical interventions and educational activities.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
7
|
Mattei G, Rioli G, Ferrari S, Bursi S, Pingani L, Rigatelli M, Galeazzi G. Association Between Symptoms of Anxiety and Depression and BMI in Primary Care Patients: a Cross Sectional Study. Eur Psychiatry 2015. [DOI: 10.1016/s0924-9338(15)30982-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
8
|
Mattei G, Simoni E, Bursi S, Rossi R, Coppi F, Gorlato G, Borghi A, Capitani C, Pingani L, Ferrari S, Rigatelli M. EPA-1226 – Consultation-liaison psychiatry and the “women wellness project”: analysis of the association between cardiovascular risk factors and psychiatric symptoms in postmenopausal women. Eur Psychiatry 2014. [DOI: 10.1016/s0924-9338(14)78469-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
9
|
|
10
|
De Maio E, Tibaldi C, D'Incecco A, Bursi S, Barbara C, Cupini S, Di Marsico R, D'Arcangelo M, Landi L, Minuti G, Cappuzzo F. Consequences of targeted treatments for second-line therapy. Ann Oncol 2010; 21 Suppl 7:vii234-40. [DOI: 10.1093/annonc/mdq280] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Fontana A, Galli L, Derosa L, Minuti G, D'Arcangelo M, Bursi S, Landi L, Bocci G, Santini D, Falcone A. 7036 Phase II study with pharmacodynamic evaluation of docetaxelprednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC). EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71414-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
12
|
Fontana A, Bocci G, Galli L, Derosa L, Minuti G, D'Arcangelo M, Santini D, Landi L, Bursi S, Falcone A. Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration resistant prostate cancer (CRPC) patients (Pts). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16032 Background: Metronomic oral CTX and C has demonstrated activity and a favourable toxicity profile in CRCP. Combination of such strategy with the standard DP could be of interest. Methods: Pts with CRPC received D 60 mg/sqm iv day 1 every 3 weeks up to 12 cycles and from day 2 continuously: P 5 mg po BID, CTX 50 mg po daily, and C 200 mg po BID. Primary objective is the percentage of pts free of progression at 6 months; secondary are: PSA levels decrease ≥ 50%, objective responses (RECIST), toxicities (NCI-CTC criteria) survival and pharmacodynamic evaluations. Results: To date 29 pts have been enrolled. Main pts characteristics are: median age 72 years (52–78 years), median PS 0 (0–2), median baseline PSA level 38,8 ng/mL (2.5–1309 ng/mL); main sites of disease: bone 23 pts (79%), lymphnodes 6 pts (21%), liver 1 pt (3,5%). Twenty-nine pts are evaluable for toxicity whereas 28 for PSA response (1 pt abandoned the study due to allergic reaction after first D administration). Median number of D cycles delivered is 10 (1–12) and median duration of metronomic CTX plus P and C is 224 days (35–874 days). Main grade 3 side-effects are: neutropenia (2 pt; 7%), thrombocytopenia, diarrhoea, stomatitis and onycholysis (1 pt; 3.5%). No grade 4 toxicities have been observed.The rate of pts free of progression at 6 months is 80%. Overall 18 pts (64%) showed a PSA decrease ≥ 50% and 23 pts (82%) showed any PSA decrease from baseline (range: 4%-99%of decrease). Four pts are evaluable according to RECIST criteria: we observed 1 CR, 2 SD and 1 PD. At a median follow up of 12,4 months median time to PSA progression is 11.6 months (95% CI 8,3–15). Conclusions: Metronomic CTX plus C in combination with DP is a feasible and tolerable regimen with a promising preliminary activity. The evaluation of plasma levels of thrombospondin-1 (TSP-1), VEGF, sVEGFR-2, VE-cadherin mRNA, and the expression of TSP-1 and VEGF in peripheral blood mononuclear cells, as potential surrogated markers of antiangiogenic activity of the combination, is ongoing. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Fontana
- ASL6 and University of Pisa, ITT, Livorno, Italy; University of Pisa, Pisa, Italy; ASL6, ITT, Livorno, Italy; University Campus Bio-Medico, Roma, Italy
| | - G. Bocci
- ASL6 and University of Pisa, ITT, Livorno, Italy; University of Pisa, Pisa, Italy; ASL6, ITT, Livorno, Italy; University Campus Bio-Medico, Roma, Italy
| | - L. Galli
- ASL6 and University of Pisa, ITT, Livorno, Italy; University of Pisa, Pisa, Italy; ASL6, ITT, Livorno, Italy; University Campus Bio-Medico, Roma, Italy
| | - L. Derosa
- ASL6 and University of Pisa, ITT, Livorno, Italy; University of Pisa, Pisa, Italy; ASL6, ITT, Livorno, Italy; University Campus Bio-Medico, Roma, Italy
| | - G. Minuti
- ASL6 and University of Pisa, ITT, Livorno, Italy; University of Pisa, Pisa, Italy; ASL6, ITT, Livorno, Italy; University Campus Bio-Medico, Roma, Italy
| | - M. D'Arcangelo
- ASL6 and University of Pisa, ITT, Livorno, Italy; University of Pisa, Pisa, Italy; ASL6, ITT, Livorno, Italy; University Campus Bio-Medico, Roma, Italy
| | - D. Santini
- ASL6 and University of Pisa, ITT, Livorno, Italy; University of Pisa, Pisa, Italy; ASL6, ITT, Livorno, Italy; University Campus Bio-Medico, Roma, Italy
| | - L. Landi
- ASL6 and University of Pisa, ITT, Livorno, Italy; University of Pisa, Pisa, Italy; ASL6, ITT, Livorno, Italy; University Campus Bio-Medico, Roma, Italy
| | - S. Bursi
- ASL6 and University of Pisa, ITT, Livorno, Italy; University of Pisa, Pisa, Italy; ASL6, ITT, Livorno, Italy; University Campus Bio-Medico, Roma, Italy
| | - A. Falcone
- ASL6 and University of Pisa, ITT, Livorno, Italy; University of Pisa, Pisa, Italy; ASL6, ITT, Livorno, Italy; University Campus Bio-Medico, Roma, Italy
| |
Collapse
|
13
|
Vasile E, Masi G, Fornaro L, Cupini S, Loupakis F, Bursi S, Petrini I, Di Donato S, Brunetti IM, Ricci S, Antonuzzo A, Chiara S, Amoroso D, Andreuccetti M, Falcone A. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br J Cancer 2009; 100:1720-4. [PMID: 19436300 PMCID: PMC2695688 DOI: 10.1038/sj.bjc.6605075] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substituted in FOLFOXIRI regimen by capecitabine, an oral fluoropyrimidine with similar efficacy. Recently, a dose-finding trial has demonstrated the feasibility of the combination of irinotecan, oxaliplatin and capecitabine (XELOXIRI) and established their recommended doses. The aim of this study was to evaluate the activity of XELOXIRI. A total of 36 patients with unresectable metastatic colorectal cancer received irinotecan 165 mg m−2 and oxaliplatin 85 mg m−2 on day 1 plus capecitabine 2000 mg m−2 per day orally in two doses from day 1 to day 7, every 2 weeks. Grade 3–4 toxicities were infrequent, expect for neutropenia and diarrhoea, which were each observed in 30% of patients. Two complete and twenty-two partial responses were obtained, corresponding to an overall response rate of 67% (95% CI 51.4–82%). After a median follow-up of 17.7 months, the median progression-free and overall survival were 10.1 and 17.9 months, respectively. The substitution of 5-fluorouracil with capecitabine, in combination with irinotecan and oxaliplatin, is feasible and does not impair the activity of the regimen. However, the XELOXIRI combination is associated with a high incidence of diarrhoea and, therefore, should be considered as a not preferable alternative to FOLFOXIRI.
Collapse
Affiliation(s)
- E Vasile
- UO Oncologia Medica, Azienda USL 6, Istituto Toscano Tumori, Viale Alfieri 36, Livorno 57100, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Roncucci L, Mora E, Mariani F, Bursi S, Pezzi A, Rossi G, Pedroni M, Luppi D, Santoro L, Monni S, Manenti A, Bertani A, Merighi A, Benatti P, Di Gregorio C, de Leon PM. Myeloperoxidase-positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17:2291-7. [PMID: 18768495 DOI: 10.1158/1055-9965.epi-08-0224] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Colorectal mucosa is targeted by toxic agents, which can initiate or promote colon cancer. The mechanism of damage might be a focal irritation with loss of normal epithelial cell barrier function. Genetic alterations in tumors may also affect host inflammatory response. The aim of this study was to define the extent of inflammation in colorectal mucosa, along colorectal carcinogenesis, and in microsatellite stable and unstable colorectal carcinomas. We collected 103 samples of normal colorectal mucosa from 65 patients (35 with colorectal cancer or adenoma, 8 with inflammatory bowel diseases, and 22 controls with normal colonoscopy). We also examined 24 aberrant crypt foci, 14 hyperplastic polyps, 16 adenomas, and 67 samples of colorectal carcinoma. Immunohistochemistry was used to count myeloperoxidase (MPO)-positive cells (neutrophils and monocytes) in x100 optical fields under a light microscope. Patients with colorectal tumors had a higher mean number of MPO-positive cells in normal mucosa than controls (mean +/- SD, 2.7 +/- 2.0 versus 1.4 +/- 1.4; P = 0.017). MPO-positive cell number was tightly linked to dysplasia in aberrant crypt foci and adenomas, and it was higher in carcinomas microsatellite unstable than those microsatellite stable (21.6 +/- 15.5 versus 11.9 +/- 8.0; P < 0.01). MPO immunohistochemistry is a simple and reliable technique for the quantification of inflammation in colorectal mucosa., and it may be a potential marker of colorectal cancer risk. Microsatellite instability seems to influence host immune responses to colorectal carcinoma. These observations strongly support a key role of inflammation in colorectal carcinogenesis.
Collapse
Affiliation(s)
- Luca Roncucci
- Department of Internal Medicine, University of Modena and Reggio Emilia, Policlinico, Modena, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Fornaro L, Masi G, Bursi S, Loupakis F, Vasile E, Antonuzzo A, Chiara S, Pfanner E, Di Paolo A, Bocci G, Del Tacca M, Falcone A. A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. Cancer Chemother Pharmacol 2008; 63:965-9. [DOI: 10.1007/s00280-008-0840-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2008] [Accepted: 09/12/2008] [Indexed: 12/27/2022]
|
16
|
Fontana A, Bocci G, D’Arcangelo M, Galli L, Galli C, Bursi S, Landi L, Antonuzzo A, Del Tacca M, Falcone A. Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.16084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Bursi S, Masi G, Loupakis F, Antonuzzo A, Chiara S, Pfanner E, Petrini I, Barletta M, Baldi G, Falcone A. 3063 POSTER Capecitabine (C), in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.). EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70991-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
18
|
Cupini S, Bursi S, Masi G, Loupakis F, Barbara C, Fornaro L, Allegrini G, Di Marsico R, Andreuccetti M, Falcone A. 3051 POSTER Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC). EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70979-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
19
|
Masi G, Bursi S, Loupakis F, Barbara C, Brunetti I, Ferraldeschi R, Evangelista W, Chiara S, Granetto C, Falcone A. 3022 POSTER Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70950-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
20
|
Loupakis F, Masi G, Bursi S, Picone V, Mentuccia L, Granetto C, Fea E, Murr R, Antonuzzo A, Falcone A. Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (Ir) + 5FU/LV (IrFL) followed by docetaxel (T) + 5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologio Nord-Ovest (GONO). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15059 Background: 5FU in combination with P can be considered a standard treatment for MGC. Ir and T are active agents with not complete cross-resistance with P and 5FU. The combination of Ir or T with P and 5FU is feasible but with substantial toxicities. A different way to include Ir and T in the first-line treatment of MGC is to use them sequentially to a P and 5FU containing regimen. Methods: we conducted a phase II study of first-line sequential chemotherapy in MGC pts with measurable disease (RECIST criteria). Treatment consisted of: 3 cycles of PFL (biweekly P 50 mg/sqm d1, LV 200 mg/sqm d1 and 5FU 3200 mg/sqm 48-h c.i. starting on d1) followed by 3 cycles of IrFL (biweekly Ir 180 mg/sqm d1 and 5FU/LV) followed by 3 cycles of TFL (biweekly T 50 mg/sqm d1 and 5FU/LV). Evaluation of disease was performed every 3 cycles. Results: 46 pts have been enrolled. Pts characteristics are: median age = 60 years (37–75), M/F = 36/10, sites of disease (single/multiple) 9/37, ECOG PS 0/1 = 27/19. Treatment was well tolerated. Grade 3–4 non-haematological toxicities were: diarrhea in 2,5% pts with PFL; diarrhea and asthenia in 2,5% and stomatitis in 5% pts with IrFL; stomatitis in 5,7% pts with TFL. Grade 3/4 neutropenia was observed in 14% pts with PFL, 15% with IrFL and 22,9% pts with TFL. Nor febrile neutropenia neither toxic deaths have occurred. Two pts had not evaluable disease and 6 are still receiving treatment. We observed 1 CR and 8 PR with PFL (RR 24%) among the 38 evaluable pts. IrFL improved responses in 10 pts while 4 pts progressed and TFL further improved responses in 6 pts while 5 pts progressed. Response rate at the end of the planned 9 cycles was 40% (4 CR, 11 PR; 95% CI 25–58%). At a median follow-up of 15.5 mos median TTP is 6.8 mos and median OS is 13.5 mos. Conclusions: this sequential treatment is feasible with a very favourable safety profile and produces encouraging results in terms of activity and efficacy in a population of unselected MGC patients. Final data will be presented at the meeting. Partially supported by A.R.C.O. Foundation. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Loupakis
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - G. Masi
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - S. Bursi
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - V. Picone
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - L. Mentuccia
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - C. Granetto
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - E. Fea
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - R. Murr
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - A. Antonuzzo
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| | - A. Falcone
- Azienda USL 6, Livorno, Italy; Università La Sapienza, Roma, Italy; Ospedale S. Croce e Carle, Cuneo, Italy; Ospedale S. Chiara, Pisa, Italy; Azienda USL 6, Piombino, Italy; Università degli Studi, Pisa, Italy
| |
Collapse
|
21
|
Masi G, Bursi S, Loupakis F, Barletta M, Baldi G, Antonuzzo A, Sonaglio C, Pfanner E, Petrini I, Falcone A. The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4096] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4096 Background: FOLFOXIRI demonstrated manageable toxicities and improved activity and efficacy compared to FOLFIRI in MCRC in a phase III trial by the G.O.N.O. group. Oral C has demonstrated similar efficacy to 5-FU and might substitute 5-FU in the FOLFOXIRI regimen. Methods: The G.O.N.O. started a pilot study to evaluate the combination of escalating doses of C with fixed doses of I, O (XELOXIRI) in metastatic and not resectable CRC patients (pts). The objectives of the study are the definition of the recommended dose (RD) of C in combination with I and O, safety and activity of the combination and analysis of plasma pharmacokinetics. The planned treatment in the first 3 patients was: I 165 mg/sqm over 1-h on day 1, O 85 mg/sqm over 2-h on day 1 and C 2,500 mg/sqm/die from day 1 to 7, repeated every 2 weeks. C dose was increased to 3,000 mg/sqm/die or decreased to 2,000 mg/sqm/die in subsequent groups of 3 to 6 pts on the basis of the observed dose limiting toxicities (DLT). Results: Up today 33 patients have been enrolled. Main patients characteristic are: sex (M/F) = 22/11, PS (0/1/2) = 28/4/1, age (median/range) = 65/42–76, sites of disease (single/multiple) = 18/15. The DLT was G3–4 diarrhea that was observed in 2 out 6 patients receiving C at 2500 mg/sqm, in 2 out 3 patients receiving C at 3,000 mg/sqm and in 1 out 6 patients receiving C at 2,000 mg/sqm. This last dose was defined the RD. Among the 23 patients treated at the RD main G3–4 toxicities were: diarrhea 17%, neutropenia 26%, thrombocytopenia 9%, neurotoxicity 4%. One toxic death for diarrhea and sepsis occurred. Up today 21 out of the 23 patients (2 patients too early) treated at the RD are assessable for response (ITT analysis) and 15 RP, 3 SD and 3 treatment failures have been observed with a response rate of 71% (95% CI: 48–89%). At a median follow-up of 10.3 months median PFS is 9.0+ months and median OS isn’t yet reached. Conclusions: XELOXIRI is a feasible regimen with diarrhea being the DLT. The recommended dose of C is 2,000 mg/sqm. At the RD toxicity is manageable and preliminary results in terms of activity are promising. Partially supported by Fondazione ARCO. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- G. Masi
- Az. Usl 6, Livorno, Italy; Az. Usl 6, Piombino, Italy; IST, Genova, Italy; Ospedale S.Chiara, Pisa, Italy; Università degli Studi, Pisa, Italy
| | - S. Bursi
- Az. Usl 6, Livorno, Italy; Az. Usl 6, Piombino, Italy; IST, Genova, Italy; Ospedale S.Chiara, Pisa, Italy; Università degli Studi, Pisa, Italy
| | - F. Loupakis
- Az. Usl 6, Livorno, Italy; Az. Usl 6, Piombino, Italy; IST, Genova, Italy; Ospedale S.Chiara, Pisa, Italy; Università degli Studi, Pisa, Italy
| | - M. Barletta
- Az. Usl 6, Livorno, Italy; Az. Usl 6, Piombino, Italy; IST, Genova, Italy; Ospedale S.Chiara, Pisa, Italy; Università degli Studi, Pisa, Italy
| | - G. Baldi
- Az. Usl 6, Livorno, Italy; Az. Usl 6, Piombino, Italy; IST, Genova, Italy; Ospedale S.Chiara, Pisa, Italy; Università degli Studi, Pisa, Italy
| | - A. Antonuzzo
- Az. Usl 6, Livorno, Italy; Az. Usl 6, Piombino, Italy; IST, Genova, Italy; Ospedale S.Chiara, Pisa, Italy; Università degli Studi, Pisa, Italy
| | - C. Sonaglio
- Az. Usl 6, Livorno, Italy; Az. Usl 6, Piombino, Italy; IST, Genova, Italy; Ospedale S.Chiara, Pisa, Italy; Università degli Studi, Pisa, Italy
| | - E. Pfanner
- Az. Usl 6, Livorno, Italy; Az. Usl 6, Piombino, Italy; IST, Genova, Italy; Ospedale S.Chiara, Pisa, Italy; Università degli Studi, Pisa, Italy
| | - I. Petrini
- Az. Usl 6, Livorno, Italy; Az. Usl 6, Piombino, Italy; IST, Genova, Italy; Ospedale S.Chiara, Pisa, Italy; Università degli Studi, Pisa, Italy
| | - A. Falcone
- Az. Usl 6, Livorno, Italy; Az. Usl 6, Piombino, Italy; IST, Genova, Italy; Ospedale S.Chiara, Pisa, Italy; Università degli Studi, Pisa, Italy
| |
Collapse
|
22
|
Masi G, Marcucci L, Loupakis F, Cerri E, Barbara C, Bursi S, Allegrini G, Brunetti IM, Murr R, Ricci S, Cupini S, Andreuccetti M, Falcone A. First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Ann Oncol 2006; 17:1249-54. [PMID: 16766580 DOI: 10.1093/annonc/mdl119] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND We conducted two phase II trials evaluating the combination of 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) as first-line treatment in 74 metastatic colorectal cancer patients. Results were very promising with an overall response rate of 71% and 72%, a median PFS of 10.4 and 10.8 months and an overall survival of 26.5 and 28.4 months, respectively. A concern about the use of all three active agents up-front is the possibility that this might limit, after progression, disease control with second-line treatments. Therefore, we conducted the present analysis to evaluate the outcome of second-line treatments in these 74 patients. METHODS Among the 71 patients so far progressed 54 (76%) received second line chemotherapy (23: FOLFIRI, 17: FOLFOXIRI, five: 5-FU protracted infusion, three: FOLFOX, three: 5-FU+MMC, two: CPT-11, one: CPT-11+LOHP, one: raltitrexed). Seventeen patients (24%) did not receive second line treatments: 10 because of deterioration of performance status (PS), four because of patient refusal and three because of death. Patients' characteristics at the time of second-line treatment were: M/F 36 of 18 patients, median age 64 yrs (range 44-75), ECOG PS>or=1 21 (39%) patients, multiple sites of disease 33 (61%) patients. RESULTS A median of 4.1 months of second-line chemotherapy per patient were administered (range 1-8). Overall response rate (52 out of 54 evaluable patients) was 33% and stable disease were 19 (37%). Median duration of response was 8.1 months. At a median follow up of 15.1 months from the start of salvage chemotherapy median PFS and overall survival were respectively 6.7 and 15.2 months. CONCLUSIONS First-line FOLFOXIRI does not impair the possibility to obtain objective responses and delay tumor progression with second line treatments containing the same agents used in first-line.
Collapse
Affiliation(s)
- G Masi
- Division of Medical Oncology, Department of Oncology, Livorno, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|